Iris Behrmann
YOU?
Author Swipe
View article: Directed-Complement Activation as a Novel Immunotherapeutic Approach for HER2-Breast Cancer
Directed-Complement Activation as a Novel Immunotherapeutic Approach for HER2-Breast Cancer Open
We showed here that directed complement activation on tumor cells is an alternative to therapeutic antibodies for future combination therapies upon resistance to standard-of-care treatment.
View article: Targeting the energy metabolism of melanoma cells: FX-11 acts as a mitochondrial uncoupler
Targeting the energy metabolism of melanoma cells: FX-11 acts as a mitochondrial uncoupler Open
In a compound screen on melanoma cells, which included different microenvironmental contexts aiming at better representing the environmental and growth characteristics of tumours, we identified several drugs efficiently suppressing cell vi…
View article: Metabolism-oriented compound screen in physiological culture conditions identifies a NAMPT inhibitor highly effective against drug-naïve and -resistant melanoma cells
Metabolism-oriented compound screen in physiological culture conditions identifies a NAMPT inhibitor highly effective against drug-naïve and -resistant melanoma cells Open
Many melanoma patients do not respond to therapy or rapidly develop resistance to MAPK pathway inhibitors and immune checkpoint blockade treatments, highlighting the urgent need for additional therapeutic strategies for these patients. To …
View article: Ferroptosis susceptibility of melanoma cells: dependence on cell-type, acquired drug resistance, and medium composition
Ferroptosis susceptibility of melanoma cells: dependence on cell-type, acquired drug resistance, and medium composition Open
Resistance of melanoma cells to targeted therapy (BRAF and MEK inhibitors) is a major clinical problem and alternative treatments are sought. We describe the establishment of modular physiologic medium (MPM) and Mel-MPM (which contains add…
View article: Complement-Activating Multimeric Immunotherapeutic Complexes for HER2-breast cancer immunotherapy
Complement-Activating Multimeric Immunotherapeutic Complexes for HER2-breast cancer immunotherapy Open
Background Directing selective complement activation towards tumor cells is an attractive strategy to promote their elimination. We have generated Complement-activating Multimeric immunotherapeutic compleXes (CoMiX) that selectively stimul…
View article: Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3 I148M risk allele
Altered profiles of circulating cytokines in chronic liver diseases (NAFLD/HCC): Impact of the PNPLA3 I148M risk allele Open
Background: Individuals carrying the risk variant p.I148M of patatin-like phospholipase domain-containing protein 3 ( PNPLA3 ) have a higher susceptibility to fatty liver diseases and associated complications, including HCC, a cancer close…
Supplementary Figures S1-S4 from Constitutive Suppressor of Cytokine Signaling 3 Expression Confers a Growth Advantage to a Human Melanoma Cell Line Open
Supplementary Figures S1-S4 from Constitutive Suppressor of Cytokine Signaling 3 Expression Confers a Growth Advantage to a Human Melanoma Cell Line
Data from Constitutive Suppressor of Cytokine Signaling 3 Expression Confers a Growth Advantage to a Human Melanoma Cell Line Open
The growth of melanocytes and many early stage melanoma cells can be inhibited by cytokines, whereas late stage melanoma cells have often been reported to be “multi-cytokine–resistant.” Here, we analyzed the melanoma cell line 1286, resist…
Data from Constitutive Suppressor of Cytokine Signaling 3 Expression Confers a Growth Advantage to a Human Melanoma Cell Line Open
The growth of melanocytes and many early stage melanoma cells can be inhibited by cytokines, whereas late stage melanoma cells have often been reported to be “multi-cytokine–resistant.” Here, we analyzed the melanoma cell line 1286, resist…
Supplementary Figures S1-S4 from Constitutive Suppressor of Cytokine Signaling 3 Expression Confers a Growth Advantage to a Human Melanoma Cell Line Open
Supplementary Figures S1-S4 from Constitutive Suppressor of Cytokine Signaling 3 Expression Confers a Growth Advantage to a Human Melanoma Cell Line
View article: Supplementary Figure 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
Supplementary Figure 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma Open
Supplementary Figure 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
View article: Supplementary Table and Figure Legends, Material and Methods from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
Supplementary Table and Figure Legends, Material and Methods from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma Open
Supplementary Table and Figure Legends, Material and Methods from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
View article: Supplementary Figure 2 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
Supplementary Figure 2 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma Open
Supplementary Figure 2 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
View article: Supplementary Table 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
Supplementary Table 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma Open
Supplementary Table 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
View article: Data from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
Data from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma Open
Small noncoding microRNAs (miRNA) regulate the expression of target mRNAs by repressing their translation or orchestrating their sequence-specific degradation. In this study, we investigated miRNA and miRNA target gene expression patterns …
View article: Supplementary Figure 2 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
Supplementary Figure 2 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma Open
Supplementary Figure 2 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
View article: Supplementary Table 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
Supplementary Table 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma Open
Supplementary Table 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
View article: Data from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
Data from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma Open
Small noncoding microRNAs (miRNA) regulate the expression of target mRNAs by repressing their translation or orchestrating their sequence-specific degradation. In this study, we investigated miRNA and miRNA target gene expression patterns …
View article: Supplementary Figure 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
Supplementary Figure 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma Open
Supplementary Figure 1 from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
View article: Supplementary Table and Figure Legends, Material and Methods from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
Supplementary Table and Figure Legends, Material and Methods from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma Open
Supplementary Table and Figure Legends, Material and Methods from Signatures of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma
Distinct Cargos of Small Extracellular Vesicles Derived from Hypoxic Cells and Their Effect on Cancer Cells Open
Hypoxia is a common hallmark of solid tumors and is associated with aggressiveness, metastasis and poor outcome. Cancer cells under hypoxia undergo changes in metabolism and there is an intense crosstalk between cancer cells and cells from…
Hypoxia-Induced Adaptations of miRNomes and Proteomes in Melanoma Cells and Their Secreted Extracellular Vesicles Open
Reduced levels of intratumoural oxygen are associated with hypoxia-induced pro-oncogenic events such as invasion, metabolic reprogramming, epithelial–mesenchymal transition, metastasis and resistance to therapy, all favouring cancer progre…
View article: miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease
miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease Open
GNMT participates in the regulation of metabolic pathways and mitochondrial functionality through the regulation of Complex II activity in the electron transport chain. In NAFLD, GNMT is repressed by miR-873-5p and its targeting arises as …
Cytokine-mediated modulation of the hepatic miRNome: miR-146b-5p is an IL-6-inducible miRNA with multiple targets Open
Interleukin-6 (IL-6)-type cytokines play important roles in liver (patho-)biology. For instance, they regulate the acute phase response to inflammatory signals and are involved in hepatocarcinogenesis. Much is known about the regulation of…
View article: The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by α-PD-L1 or α-IL6 antibodies
The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by α-PD-L1 or α-IL6 antibodies Open
Interleukin-27 (IL27) is a type-I cytokine of the IL6/IL12 family and is predominantly secreted by activated macrophages and dendritic cells. We show that IL27 induces STAT factor phosphorylation in cancerous cell lines of different tissue…